Market Cap | 247.32B | P/E | 8.05 | EPS this Y | 46.40% | Ern Qtrly Grth | 5.70% |
Income | 29.95B | Forward P/E | 10.85 | EPS next Y | -24.30% | 50D Avg Chg | -10.00% |
Sales | 99.88B | PEG | 9.94 | EPS past 5Y | 17.66% | 200D Avg Chg | -9.00% |
Dividend | 4.00% | Price/Book | 2.67 | EPS next 5Y | 0.79% | 52W High Chg | -22.00% |
Recommedations | 2.20 | Quick Ratio | 1.24 | Shares Outstanding | 5.61B | 52W Low Chg | 6.00% |
Insider Own | 0.05% | ROA | 13.32% | Shares Float | 5.61B | Beta | 0.65 |
Inst Own | 70.52% | ROE | 35.51% | Shares Shorted/Prior | 58.02M/70.04M | Price | 44.06 |
Gross Margin | 66.17% | Profit Margin | 29.81% | Avg. Volume | 22,107,226 | Target Price | 55.49 |
Oper. Margin | 39.96% | Earnings Date | Jan 31 | Volume | 19,169,954 | Change | -0.63% |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Morgan Stanley | Equal-Weight | Dec 14, 22 |
Goldman Sachs | Buy | Dec 13, 22 |
Credit Suisse | Outperform | Nov 18, 22 |
SVB Leerink | Market Perform | Nov 3, 22 |
Wells Fargo | Overweight | Nov 2, 22 |
Barclays | Equal-Weight | Nov 2, 22 |
Morgan Stanley | Equal-Weight | Nov 2, 22 |
Morgan Stanley | Equal-Weight | Oct 12, 22 |
Barclays | Equal-Weight | Oct 12, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
LANKLER DOUGLAS M | Executive Vice Presi.. Executive Vice President | Dec 14 | Option | 26.53 | 101,658 | 2,696,987 | 180,461 | 12/16/22 |
BOURLA ALBERT | Chairman & CEO Chairman & CEO | Dec 15 | Option | 26.53 | 222,328 | 5,898,362 | 411,890 | 12/16/22 |
DAMICO JENNIFER B. | SVP & Controller SVP & Controller | May 13 | Sell | 50.5000 | 4,000 | 202,000 | 15,064 | 05/17/22 |
SAHNI PAYAL | Executive Vice Presi.. Executive Vice President | May 13 | Sell | 49.8400 | 1,408 | 70,175 | 17,372 | 05/16/22 |
Carapezzi William R JR | Executive Vice Presi.. Executive Vice President | May 12 | Sell | 50.0000 | 32,908 | 1,645,400 | 38,146 | 05/13/22 |
LANKLER DOUGLAS M | Executive Vice Presi.. Executive Vice President | May 12 | Sell | 49.4100 | 38,273 | 1,891,069 | 78,803 | 05/13/22 |
Dolsten Mikael | President R&D President R&D | May 11 | Sell | 49.34 | 63,902 | 3,152,925 | 333,342 | 05/12/22 |
SUSMAN SALLY | Executive Vice Presi.. Executive Vice President | Feb 26 | Option | 25.6 | 63,580 | 1,627,648 | 172,880 | 03/01/22 |
DAMELIO FRANK A | Executive Vice Presi.. Executive Vice President | Feb 26 | Option | 25.6 | 127,160 | 3,255,296 | 649,918 | 03/01/22 |
SUSMAN SALLY | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 76,895 | 2,102,309 | 166,470 | 02/25/22 |
SAHNI PAYAL | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 13,884 | 379,589 | 29,391 | 02/25/22 |
LANKLER DOUGLAS M | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 115,342 | 3,153,450 | 181,659 | 02/25/22 |
JOHNSON RADY A | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 35,457 | 969,394 | 91,301 | 02/25/22 |
Hwang Angela | Group President Group President | Feb 23 | Option | 27.34 | 21,359 | 583,955 | 21,359 | 02/25/22 |
DAMELIO FRANK A | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 153,789 | 4,204,591 | 636,977 | 02/25/22 |
DAMICO JENNIFER B. | SVP & Controller SVP & Controller | Feb 23 | Option | 27.34 | 11,748 | 321,190 | 21,668 | 02/25/22 |
Carapezzi William R JR | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 25,632 | 700,779 | 82,914 | 02/25/22 |
YOUNG JOHN D | Group President Group President | Nov 11 | Sell | 50.09 | 150,000 | 7,513,500 | 312,704 | 11/12/21 |